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Review Paper 
Cancer is a leading cause of death worldwide. Due 
to substantial improvements in early detection and 
treatment, the mortality rate has decreased in recent 
years, but treatment of many cases remains quite 
sophisticated (1). Colorectal cancer is the third major 
cause of cancer deaths in the United States both in 
men and women.  Novel therapeutic strategies are 
under investigation including using nanoparticles (2). 
In this brief review different aspects of using 
nanoparticles in colorectal cancer stem cell are 
discussed.  
Cancer Stem Cell  
Cancer stem cells (CSCs) are small subpopulations 
of tumor cells responsible for the spread of cancer 
and tumor growth in a very efficient manner (3). 
Perhaps one of the most important causes of relapse 
and resistance to treatment is that the CSCs are not 
affected despite the administration of common 
therapeutic agents (4). CSCs have the ability of 
infinite self-renewal and the capacity to differentiate 
into the various populations of cells that comprise a 
tumor.  
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Colorectal cancer (CRC) is the third major cause of cancer death globally, 
with about 694,000 deaths each year. Recent studies have shown that cancer 
stem cells (CSCs) play an important role in cancer relapse and metastasis. 
Inhibition of COX-2, Wnt / beta-catenin, HIF-1 alpha, K-Ras, NF-kβ, P53 
signaling pathways and activation of TGF-β are amongst proposed strategies 
against colorectal cancer. Specific markers of CSCs including CD133, 
CD24, CD29, CD44 and Lgr5 are also of importance in diagnosis and 
monitoring of the disease. Therefore, the use of nanoparticles can be 
discussed in two different fields: 1. using nanoparticles in diagnosis and 
targeting CSCs, 2. targeting the cancer cells directly, where nanoparticles 
can affect the cell signaling pathways and expression patterns to prevent 
extension of tumor cells. In addition, nanoparticles can be used as the 
carriers for anti-cancer drugs and drug delivery, which in turn may enhance 
effectiveness of treatment.  This review covers the novel signaling pathways 
in colorectal cancer and also gives a brief explanation about the role of some 
nanostructures that enhance treatment efficiency.  
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Self-renewal refers to the ability to create new stem 
cells with the same properties such as potential 
proliferation, development, and differentiation, 
thereby maintaining the stem cell population. 
Induction of cancer stem cells to differentiate, may 
result in removal of their ability of self-renewa (5). 
A niche is a special microenvironment where stem 
cells are stored and characterized with having 
different factors that can control stem cell 
proliferation and determination. In general, the niche 
is kept in a state of stasis by creating a signal that 
inhibits the growth and proliferation of stem cells 
(6). Stem cells can only get activated in presence of 
the excitation signals which make them start 
dividing and going into proliferation. Therefore the 
balance between proliferation and inhibitory signals 
is the key for stem cell homeostasis. Any disruption 
increases the risk of developing tumors (7). 
 
Colorectal Cancer Stem Cells and Markers 
Several studies identified a subpopulation of 
colorectal cancer cells that are more resistant to 
cancer treatment methods (such as chemotherapy 
and radiation therapy). Effective treatment depends 
on the elimination of these resistant subpopulations. 
These cancer stem cells or tumor-initiating cells 
have several highly expressed markers on their cell 
surface (8). Important markers in colorectal cancer 
stem cells are CD24, CD29, LGR5, CD133 and 
CD44 (9). 
CD24 is a cell surface protein that is attached to the 
outer plasma membrane. CD24+ subpopulations 
have cancer stem cell-like properties such as 
increased resistance to chemotherapy, self-renewal 
and potential tumorigenesis both in vitro and in vivo, 
compared to CD24- cell subpopulations (10). 
CD29 (B1- integrin) is a member of the integrin 
family and contains a large extracellular and a short 
cytoplasmic domain that acts as a receptor for 
extracellular matrix proteins. It also activates 
signaling pathways to regulate cell migration, 
proliferation, permanence, differentiation and death. 
CD29 also plays a role in the higher activity of 
colorectal cancer cell metastasis (11).  
LGR5 is a member of the Wnt signaling pathway. 
Although its ligand is unclear, it is one of the stem 
cell markers in the intestinal crypts. The findings 
show that LGR5 could play a key role in the 
development of CRC and may be considered as a 
useful marker for identifying and / or targeting 
colorectal cancer stem cells (11).  
CD133 (or prominin-1) is a glycoprotein which is 
encoded by the PROM1 gene in humans. While the 
accurate function of CD133 is not clear yet, it 
appears to act as an organizer of the cell membrane 
topology. However, the findings indicate that CD133 
plays a key role in the initiation and progression of 
colorectal cancer and can be used as a marker of 
prognosis and diagnosis of CRC (10, 12). 
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assembly of growth factors on the cell surface. 
Research has shown that CD44 could have a more 
decisive role in the tumorigenesis of colorectal 
cancer cells. Furthermore, active participation in 
many cellular activities, such as survival, 
differentiation, and migration are some other 
properties of CD44 (10, 13). 
An effective treatment should be able to target all 
the different microenvironments of colon cancer stem 
cells in tumours to inhibit primary tumor growth, 
metastasis and recurrence of cancer. A promising 
method for increasing the efficiency of the treatment, 
is the use of nanoparticles in the diagnosis and 
treatment process. Biocompatible nanoparticles are 
conjugated with specific monoclonal antibodies 
against CCSC markers and also are capable of 
carrying drugs or small selectively directed RNAs to 
silence fundamental molecules for CCSC survival
(14).  
There are monoclonal antibodies such as specific 
anti-human CD133 mAb, anti human CD29 
monoclonal antibody-clone 12G10, SWA11 mAb 
and KM4056 mAb for CD133, CD29 , CD24 and 
LGR5 antigens respectively. For a more effective and 
specific drug delivery, it is suggested to target 
colorectal cancer stem cells with specific antibody 
conjugated with nanoparticles which contain loaded 
drug (15).  
Inhibition of the expression of P53, HIF-1α and 
COX-2 genes as well as inhibition of NF-kβ, Wnt / β-
catenin and K-Ras signaling and also activation of 
TGF-β are strategies for the treatment of colorectal 
cancer (16). Pending strategies for eradication of 
colorectal cancer stem cells are as follows: PI3K 
signaling impairment causes Inhibition of 
proliferation and apoptosis induction hedgehog 
signaling impairment causes proliferation impairment 
and apoptosis induction Notch signaling impairment 
causes a decrease in tumor growth and reduction in 
CCSCs frequency Inhibition of IL-4 signaling causes 
sensitization to chemotherapy CD44 silencing causes 
apoptosis induction and tumors growth suppression
(17). 
 
Nanotechnology and Gene Expression Regulation  
Nano Script is an artificial nanoparticle with similar 
functional Transcription Factor (TF) protein that in 
fact is a platform for regulating gene expression.  TF 
is a binding protein to specific sequence of DNA, so 
regulates the rate of transcription of genetic 
information from DNA to messenger RNA. Nano 
Script has two interesting features that make it 
appropriate platform in the field of stem cells: First, it 
is non-viral, that is a good alternative to viral vectors. 
Second, simple arrangement of the sequence of any 
molecule on Nano Script is possible so they can 
specifically target and induce differentiation (15). 
Liu et al developed a new nanostructure which 
contains a combination of cross-linked hydrophilic 
polymers with lipids.   
This nanostructure can be used for the delivery of 
anticancer drug and SIRNA, targeting colon cancer 
stem cells (including CD133 + cells). Using this 
approach leads to inhibition of the MDR1 activity 
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(multidrug-resistant gene) resulting in efficiency of 
treatment (18). 
There have been several other attempts to enhance 
the efficacy of different anti-cancer drugs. Curcumin 
is well known for its anti-cancer properties. 
However, due to the insolubility of this herbal drug 
in water, its use is limited. Wang et al, have 
developed the stearic acid-g-chitosan 
oligosaccharide polymeric micelles (CSO-SA) to 
overcome such problem. Micelles CSO-SA / 
curcumin made in dimensions of 115 nm, has 
increased the efficiency of anticancer effects of 
curcumin about 6 times and caused to eliminate 
colorectal cancer stem cells in-vitro. The ratio of 
expression CD44 + / CD24 + in the complex CSO-
SA-Cur are Less than curcumin only. Also, in 
intravenous injection, CSO-SA-Cur micelles inhibit 
tumor growth and suppress enrichment of cancer 
stem cells (17). 
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Conclusion 
In this review, we discussed the important role of cancer stem cells in cancer recurrence with a view of the 
roles of genes and signaling pathways in the progression of colorectal cancer. Use of nanotechnology can help 
to modulate the expression of genes and signaling pathways in cancer therapy for targeting cancer stem cells 
to increase efficiency of treatment. 
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